Varnimcabtagene autoleucel (ARI‑00001) in relapsed or refractory mantle cell lymphoma
This phase 2, open‑label, single‑arm, multicentre study evaluated the efficacy and safety of relmacabtagene autoleucel (relma‑cel), an anti‑CD19 chimeric antigen receptor T‑cell therapy, in Chinese patients with heavily pretreated relapsed/refractory mantle cell lymphoma (R/R MCL).
Evidence level: Megerősített klinikai bizonyíték. Több vagy erősebb humán vizsgálat támogatja.
Related signals
- Mantle Cell Lymphoma: Are New Therapies Changing the Standard of Care?
- Mantle cell lymphoma artificial intelligence prognostic index using hematoxylin and eosin histology
- Refining risk stratification for mantle cell lymphoma: integrating novel combination treatments and personalized approaches.
- Disease progression more than 6 years after treatment impacts overall survival in mantle cell lymphoma
- Hairy Cell Leukemia: Clinical Characteristics and Outcomes from a Single Center in the Middle East and North Africa